Evidence map›Paper›PMID 32805983›Full record

ArticleACS applied materials & interfaces2020

Modulating Lipoprotein Transcellular Transport and Atherosclerotic Plaque Formation in ApoE

Valentina Di Francesco, Danila Gurgone, Roberto Palomba, Miguel Filipe Moreira Marques Ferreira, Tiziano Catelani, Antonio Cervadoro, Pasquale Maffia, Paolo Decuzzi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Observational
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Multiscale physics-basedFrontiers in drug delivery · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Valentina Di FrancescoLaboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.ORCID http://orcid.org/0000-0003-4216-724X
Danila GurgoneCentre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, United Kingdom.ORCID http://orcid.org/0000-0001-7736-1187
Roberto PalombaLaboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.ORCID http://orcid.org/0000-0002-9715-3876
Miguel Filipe Moreira Marques FerreiraLaboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.ORCID http://orcid.org/0000-0002-1560-3571
Tiziano CatelaniElectron Microscopy Facility, Istituto Italiano di Tecnologia, via Morego 30, Genova 16163, Italy.ORCID http://orcid.org/0000-0002-3790-5749
Antonio CervadoroLaboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.ORCID http://orcid.org/0000-0003-3087-2363
Pasquale MaffiaCentre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, United Kingdom.ORCID http://orcid.org/0000-0003-3926-4225
Paolo DecuzziLaboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.ORCID http://orcid.org/0000-0001-6050-4188
Italian Institute of Technology · ITUniversity of Naples Federico II · IT

Funding

British Heart Foundation PG/19/84/34771British Heart Foundation RE/13/5/30177Wellcome Trust
6 · The paper itself

Abstract

Macrophage inflammation and maturation into foam cells, following the engulfment of oxidized low-density lipoproteins (oxLDL), are major hallmarks in the onset and progression of atherosclerosis. Yet, chronic treatments with anti-inflammatory agents, such as methotrexate (MTX), failed to modulate disease progression, possibly for the limited drug bioavailability and plaque deposition. Here, MTX-lipid conjugates, based on 1,2-distearoyl-

Indexed as

AnimalsAnti-Inflammatory AgentsApolipoproteins EAtherosclerosisATP Binding Cassette Transporter 1Diet, High-FatInterleukin-1betaLipoproteins, LDLLiposomesMacrophagesMethotrexateMiceMice, Inbred C57BLMice, KnockoutNanomedicineNanoparticles1,2-distearoylphosphatidylethanolamineAnti-Inflammatory AgentsApolipoproteins EATP Binding Cassette Transporter 1Interleukin-1betaLipoproteins, LDLLiposomesMethotrexateoxidized low density lipoproteinPhosphatidylethanolaminesatherosclerosisfoam cellsinflammationlow-density lipoprotein transportnanomedicine

Identifiers

PMID32805983
PMCPMC7453397
OpenAlexW3046198525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.